Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q2 2024
Net profit, assets, equity and cash flow for Q2 2024, against the same period a year earlier, from the published financial statements.
Net profit-60.89 millionEGP · −406.1% vs the same period a year earlier
Total assets517 millionEGP · −34.5% vs the same period a year earlier
Shareholders' equity27.35 millionEGP · −93.1% vs the same period a year earlier
Operating cash flow-30.32 millionEGP · −140.3% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q2 2024 was about -60.89 million EGP, down −406.1% from 19.89 million EGP in Q2 2023.
- Total assets at the end of Q2 2024 were about 517 million EGP, and shareholders' equity about 27.35 million EGP.
- Operating cash flow for Q2 2024 was negative at 30.32 million EGP.
Key lines against the same period a year earlier
This periodQ2 2023Change
Net profit-60.89 million19.89 million−406.1%
Gross profit64.6 million130 million−50.1%
Total assets517 million789 million−34.5%
Total liabilities490 million393 million+24.7%
Shareholders' equity27.35 million396 million−93.1%
Total liabilities and equity517 million789 million−34.5%
Operating cash flow-30.32 million75.15 million−140.3%
Investing cash flow-27.47 million-2.42 million−1036.7%
Financing cash flow17.59 million15.6 million+12.7%
Net change in cash-40.2 million88.33 million−145.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy